People
BioTime Names Brian Culley as Chief Executive Officer
20 September 2018 - - US-based biotechnology company BioTime, Inc.'s (NYSE American: BTX) board of directors has implemented a new leadership structure under which Brian Culley has been appointed as the company's chief executive officer and as a member of its board of directors, effective 17 September, the company said.

Culley succeeds co-CEOs Adi Mohanty and Dr. Michael West.

Brian Culley is an experienced public biopharmaceutical company CEO, having served in that capacity for seven years at Mast Therapeutics, which merged in 2017 with Savara, Inc. (NASDAQ: SVRA).

His experience includes the clinical development of pharmaceutical products from research through Phase 3, corporate partnering, institutional capital raising, and numerous other activities.

Culley's earlier positions include leadership roles in business development and technology transfer and as an early discovery researcher for Neurocrine Biosciences (NASDAQ: NBIX).

West will now be the full-time CEO of AgeX. AgeX and BioTime will continue their close connection through the structure of their licenses and contracts. 

BioTime is a clinical-stage biotechnology company focused on degenerative diseases. Its clinical programs are based on two platform technologies: cell replacement and cell/drug delivery.

With its cell replacement platform, BioTime is producing new cells and tissues with its proprietary pluripotent cell technologies.

These cells and tissues are developed to replace those that are either rendered dysfunctional or lost due to degenerative diseases or injuries. BioTime's cell/drug delivery programs are based upon its proprietary HyStem cell and drug delivery hydrogel matrix technology.

HyStem was designed, in part, to provide for the transfer, retention and/or engraftment of cellular replacement therapies. HyStem is a unique hydrogel that has been shown to support cellular attachment and proliferation in vivo.

Current research at leading medical institutions has shown that HyStem is compatible with a wide variety of cells and tissue types including brain, bone, skin, cartilage, vascular and heart tissues.

Due to the unique cross-linking chemistry, HyStem hydrogels have the ability to mix cells, biologics and small molecule drugs and can be injected or applied as a gel which allows the hydrogel to conform to a cavity or space.

This property of HyStem hydrogels offers several distinct advantages over other hydrogels, including the possibility of combining bioactive materials with the hydrogel at the point of use. 

BioTime is also developing HyStem for the delivery of therapeutic drugs and cells to localized areas of the body, including for sustained drug release in the targeted anatomical sites. BioTime's lead cell delivery clinical programme is Renevia, which consists of HyStem combined with the patient's own adipose derived tissue or cells.

AgeX Therapeutics, Inc., an affiliate of BioTime, Inc. (NYSE American: BTX), is a biotechnology company focused on the development of novel therapeutics for age-related degenerative disease.

The company's mission is to apply the proprietary technology platform related to telomerase-mediated cell immortality and regenerative biology to address a range of diseases of aging.

The current preclinical development efforts include two cell-based therapies derived from telomerase-positive pluripotent stem cells and two product candidates derived from the company's proprietary induced Tissue Regeneration technology.
Login
Username:

Password: